Coronary artery disease (CAD) remains a major cause of morbidity and mortality despite major improvements in primary and secondary prevention strategies. Percutaneous coronary intervention (PCI) or surgical revascularisation may be indicated in many patients with acute or stable CAD. 1
chronic renal failure are at even higher risk of developing this type of CAD. 21, 22 The prognostic implications of SVD are important since a small reference vessel diameter in the coronary segment undergoing PCI is significantly and directly associated with an increased risk of adverse clinical events, including ISR and stent thrombosis (ST) compared with larger reference vessel diameters. 9, 23 The goal of PCI is to improve the minimum lumen diameter in a given target coronary segment, which has a specific reference vessel diameter (roughly defined as the average of the diameters of apparently normal segments localised proximally and distally to the target segment). 20 Thus, the minimum lumen diameter increases significantly after the procedure but decreases at follow-up, mainly because of recoil and hyperplasia phenomena ( Figure 2 ). Stent implantation results in arterial injury, initiating a vasculoproliferative cascade with smooth muscle cell proliferation and migration resulting in neointimal hyperplasia. The amount of neointimal hyperplasia is largely independent of vessel size, and thus the absolute amount of late lumen loss -an angiographic measure of neointimal hyperplasia -is similar across a wide range of vessel diameters. 24 Therefore, small vessels are more prone to restenosis than larger vessels because they are less able to accommodate neointimal tissue without compromising blood flow. 25 Late lumen loss is defined as the difference between the postprocedural minimum lumen diameter and minimum lumen diameter at follow-up, and ranges between 0.05 and 0.10 mm (for the most effective DES) and 1.0 and 1.5 mm (for balloon-only PCI; Figure   2 ). 20, 25 While a low late loss is generally beneficial, it appears even more important in SVD ( Figure 3 ).
Drug-coated Balloons: The Technology
DCBs have been developed to overcome some of the limitations of DES, especially for patients with SVD. 6, 7, 8, 26 DCBs are semi-compliant angioplasty balloons covered with an antiproliferative drug that is rapidly released from a lipophilic matrix upon contact with the vessel wall. Mechanical expansion of the vessel is combined with release of an antiproliferative drug without leaving a foreign body. The development of DCBs is complex and factors other than the active drug itself contribute to its effect. The lipophilic matrix must maintain the drug on the balloon during transit to the lesion, while at the site of dilatation it should ensure a rapid and homogenous drug transfer to the vessel wall.
Pharmacokinetic characteristics of each DCB largely depend on the carrier and manufacturing process used to develop the coating. A variety of carrier excipients, such as iopromide, urea and shellac, among others, have been investigated to determine their ability to enhance drug delivery. 27 Most currently available DCBs use paclitaxel because of its highly lipophilic profile, potent antiproliferative effect and chemical stability after delivery. 28 The -limus drugs (sirolimus and zotarolimus), which are much less lipophilic than paclitaxel, have also shown some efficacy in the suppression of neointimal growth in a limited number of animal models. 29, 30 Several types of DCBs have been introduced in the market and approved for coronary use ( Table 1) . Current research is focused on different coatings and drug delivery technologies using -limus drugs and nanocarriers to identify optimal nanoparticle structure for efficient transfer of drugs to all layers of the vessel wall, achieving high tissue concentrations that persist days after application with a low rate of systemic drug leak. 30, 31 However, clinical data are still sparse.
The DCB technique has been successfully tested in ISR, where good clinical efficacy was demonstrated in most studies, but not in all. 15, 16, [32] [33] [34] [35] [36] [37] [38] [39] Current guidelines recommend the use of DCBs for patients with coronary ISR (class I, level of evidence A). 1, 40 In addition, DCBs are now increasingly being seen as an attractive option for the treatment of SVD and bifurcation lesions. 27, 28 Native vessels treated by DCBs, due to absent metallic struts and polymer, keep their vasomotion properties reducing abnormal flow patterns without the risk of ISR and late ST, and remain possible targets for coronary artery bypass grafts. 41 
After lesion preparation, taking care to avoid geographic mismatch, a DCB is inflated at nominal pressure for at least 30 seconds. Implantation of a DES is recommended in case of a major dissection (type C or higher), a residual stenosis of >30%, or reduced flow ( Figure 4) .
Although previous studies have not been powered to determine the optimal duration of dual antiplatelet therapy (DAPT), the available data suggests that it is required for a shorter time after DCBs compared with DES, which may be beneficial in many patient groups. The lack of a metallic scaffold and the shorter period of post-procedure inflammation, virtually eliminates the risk of thrombosis. 42 Most studies with DCBs in ISR or SVD used a short period of DAPT of only 1 month, without a higher rate of thrombotic events. 15, 17, 33, 43 Thus, a short period of DAPT in patients with stable coronary artery disease treated with
DCBs alone seems to be safe and effective.
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Conclusion
The treatment of CAD with DCBs benefits from local drug delivery and a 'leave nothing behind' strategy. Many experimental and clinical studies have demonstrated that DCBs are safe and effective for certain indications. While evidence of the value of DCBs in patients presenting with ISR is overwhelming, DCBs also appear promising for selected de novo coronary lesions in SVD. Further studies are required to ascertain the long-term benefits of DCB compared with new-generation DES in this setting before unrestricted use of DCB can be recommended.
